Certara

Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve worldwide equity in health. CGH is a new product development innovation practice inspired by Certara’s drug development and scientific due diligence work for the Bill & Melinda Gates Foundation.

Certara has announced the introduction of Certara Integral, its data repository for collecting, managing, and storing multiple types of data sets for analysis, sharing and reporting of clinical pharmacology, pharmacometrics and other relevant clinical data.

Certara, a provider of model-informed drug development, regulatory science, real-world evidence and market access services, has announced four senior executive appointments in its Simcyp division

Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360.

D360 v19.1 expands the platform’s capabilities for biologists and biologics scientists, deepens support for small molecule chemistry, and provides workflow enhancements based on community feedback. This latest version of D360 takes its name from its calendar release date; this is the first new release in 2019.

Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 18 of its Simcyp Population-based Simulator

Certara has announced that the US Food and Drug Administration (FDA) has renewed, and in many cases increased, its number of Certara software licenses for reviewing new drug and biologics applications

Certara, a provider of model-informed drug development, has announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s world-class data access capabilities

Certara has reported that 95 per cent of novel new drug approvals by the US Food and Drug Administration (FDA) in the first half of 2018 was supported by Certara software or services